Accessibility Menu
TNF Pharmaceuticals, Inc. logo

TNF Pharmaceuticals, Inc.(NASDAQ) QCLS

Current Price$3.31
Market Cap$26.78MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 Year-100%
1 Year-74%
1 Month-15%
TNF Pharmaceuticals, Inc. last closing stock price
MetricPriceDate
Last closeUSD 3.412026-07-21
TNF Pharmaceuticals, Inc. stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.16%USD 3.452026-07-14
1 month-15.17%USD 4.022026-06-18
3 month-10.97%USD 3.832026-04-22
Year to date-14.54%USD 3.992025-12-31
1 year-73.65%USD 12.942025-07-21
3 year-99.88%USD 2,820.002023-07-21
5 year-99.98%USD 15,750.002021-07-22
Since inception-99.98%USD 14,850.012021-04-20

TNF Pharmaceuticals, Inc. Financials at a Glance

Market Cap

$26.78MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$11.75M

EPS (TTM)

-$21.21

P/E Ratio

-0.16

Dividend

$0.00

Beta (Volatility)

1.31 (Average)

Price

$3.31

Volume

153,277

Open

$3.37

Previous Close

$3.31

Daily Range

$3.30 - $3.43

52-Week Range

$2.50 - $17.39

Estimated Earnings Date

Apr 10, 2026

QCLS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About TNF Pharmaceuticals, Inc.

TNF Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies. The company specializes in two primary drug platforms: MYMD-1, aimed at regulating the immune system to treat autoimmune diseases and age-related conditions, and Supera-CBD, a synthetic cannabinoid targeting neurological disorders.

Products and Services

MYMD-1: A clinical-stage immunometabolic regulator targeting autoimmune diseases like rheumatoid arthritis and age-related diseases such as sarcopenia.

Supera-CBD: A synthetic analog of CBD developed to treat conditions like epilepsy, pain, and anxiety by interacting with specific receptors.

What Makes TNF Pharmaceuticals, Inc. Special

TNF Pharmaceuticals distinguishes itself with its dual-drug platform approach, focusing on immunometabolism and synthetic cannabinoids. This strategy targets both autoimmune dysfunctions and conditions associated with neurological and psychological health, offering oral treatment options that are potentially safer and more convenient compared to current injectable therapies.

Five Things You Need to Know

The company's lead candidate, MYMD-1, is in Phase 2 trials for sarcopenia, with plans to expand into other autoimmune diseases like rheumatoid arthritis.

Supera-CBD, differentiated from natural CBD by being synthetic, bypasses regulatory challenges related to psychoactive elements.

TNF Pharmaceuticals holds a broad patent portfolio, crucial for safeguarding its proprietary technologies and competitive advantage.

The company is engaged in strategic research collaborations, including studies with Bascom Palmer Eye Institute on potential new applications for its products.

Despite the promising pipeline, TNF Pharmaceuticals has no current products on the market, meaning its potential success heavily depends on future trial results and FDA approvals.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

2

CEO

Christopher C. Chapman, Jr., MD

Website

www.qctechnologies.com

Headquarters

New York, NY 10036, US

QCLS Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-65.21%

Return on Capital

-45.27%

Return on Assets

-30.67%

Earnings Yield

-6.25%

Dividend Yield

0.00%

Payout Ratio

-1.15%

Stock Overview

Market Cap

$26.78MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

7.85M

Volume

153.28K

Avg. Volume

408.42K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$9.23M

EBITDA

-$8.93M

Operating Cash Flow

-$9.71M

Capital Expenditure

$0.00

Free Cash Flow

-$9.71M

Cash & ST Invst.

$12.97M

Total Debt

$0.00

TNF Pharmaceuticals, Inc. Performance Analysis

TNF Pharmaceuticals, Inc. annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
TNF Pharmaceuticals, Inc. sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
TNF Pharmaceuticals, Inc. annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1,174.26-54.1%
20232023-12-31USD -532.80-54.6%
20242024-12-31USD -1,114.54109.2%
20252025-12-31USD -8.66-99.2%
TNF Pharmaceuticals, Inc. sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3051.3%
Q32025-09-3085.8%
Q42025-12-3166.0%
Q12026-03-3177.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$26.78MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$8.93M

N/A

Employees

3

N/A

Net Income

-$1.24M

-10.5%

EBITDA

-$1.24M

-10.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$12.97M

+120.7%

Total Debt

$0.00

-100.0%

Accounts Receivable

$16.80K

+576.9%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-30.67%

N/A

Return on Invested Capital

-26.68%

N/A

Free Cash Flow

-$3.29M

-24.5%

Operating Cash Flow

-$3.29M

-24.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HPAIHelport AI Limited
$0.52+14.91%
APCXAppTech Payments Corp.
$0.27+16.52%
GITSGlobal Interactive Technologies, Inc.
$2.05-9.29%
JDZGJIADE Limited
$50.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$23.04+0.04%
ONDSOndas
$8.00+0.04%
SMCISuper Micro Computer
$30.56+0.20%
AALAmerican Airlines Group
$14.79-0.03%

Questions About QCLS

What is the current price of TNF Pharmaceuticals, Inc.?

TNF Pharmaceuticals, Inc. is trading at $3.31 per share.

What is the 52-week range for TNF Pharmaceuticals, Inc.?

Over the past 52 weeks, TNF Pharmaceuticals, Inc. has traded between $2.50 and $17.39.

How much debt does TNF Pharmaceuticals, Inc. have?

As of the most recent reporting period, TNF Pharmaceuticals, Inc. reported total debt of $0.00.

How much cash does TNF Pharmaceuticals, Inc. have on hand?

TNF Pharmaceuticals, Inc. reported $1.13M in cash and cash equivalents in its most recent financial results.

What is TNF Pharmaceuticals, Inc.’s dividend yield?

TNF Pharmaceuticals, Inc. does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services